Case todayNot read todayThesis-Break EngineThe case · holding · Nov 8, 2026Own NMTC if NeuroOne’s value depends on converting FDA-cleared thin-film electrode and OneRF ablation products into growing, high-margin commercial sales via its Zimmer distribution partnership while controlling R&D and commercialization spend.5 conditions2 strengthening · 3 holdingNext resultsNot scheduledNo date filed yet

NMTC at a glance

Insider buying, 7 days

Filings

None filed this week

Form 4s filed
Nov 16 – Nov 22

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

NMTC price history

Latest price$0.65Today−$0.02 (-3.38%)
NMTC -31.25%S&P 500 -10.82%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

5 MATERIAL PROPOSITIONS
  • Sustained revenue growth will be driven primarily by converting FDA 510(k) clearances and the Zimmer distribution license into repeat hospital and clinician purchases rather than one‑time milestone receipts or isolated limited releases.HoldingMateriality: High

    Revenue grew from $1.95M (FY2023) to $3.45M (FY2024) to $9.10M (FY2025), showing conversion into product sales. If commercial adoption via Zimmer scales, revenue and operating leverage will follow; if adoption stalls, the company will need more capital or face write‑downs.

    Watch: Zimmer fails to ramp commercialization or reduces promotion for Evo/OneRF, leaving NeuroOne to build sales capacity itself.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Revenue grew from $1.95M (FY2023) to $3.45M (FY2024) to $9.10M (FY2025), showing conversion into product sales.

    Open source ↗
  • Gross margins will stay positive and expand as higher‑volume sales of proprietary thin‑film electrodes and OneRF systems scale because these products carry favorable manufacturing economics vs. early R&D costs.StrengtheningMateriality: High

    Gross profit increased materially from $0.46M (FY2023) to $1.08M (FY2024) to $5.14M (FY2025), indicating improving product economics as sales rose. Sustained positive gross margins enable gross profit to cover fixed SG&A and accelerate path to operating profitability.

    Watch: Supplier cost inflation or tariffs materially raise component costs (MD&A cites supplier price increases and tariffs).

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Gross profit increased materially from $0.46M (FY2023) to $1.08M (FY2024) to $5.14M (FY2025), indicating improving product economics as sales rose.

    Open source ↗
  • Operating losses will shrink as revenue scales and SG&A/R&D spending becomes more leveraged, moving operating income toward break‑even without outsized additional R&D or commercialization spend.StrengtheningMateriality: Medium

    Operating loss improved from $(11.89)M (FY2024) to $(4.23)M (FY2025), indicating leverage or one‑time items improving operating results. Progress to operating profitability reduces dilution risk and supports equity value; failure to achieve leverage forces additional financing at dilutive terms.

    Watch: Company must materially increase commercialization spending (field sales, training) beyond current plans to penetrate hospitals outside Zimmer’s support.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Operating loss improved from $(11.89)M (FY2024) to $(4.23)M (FY2025), indicating leverage or one‑time items improving operating results.

    Open source ↗
  • The company has sufficient near‑term cash runway to fund commercialization activity through FY2026 without immediate additional dilutive financing, provided operating cash outflow remains near FY2025’s level.HoldingMateriality: Medium

    Cash increased from $1.46M (9/30/2024) to $6.57M (9/30/2025), reflecting April 2025 financing proceeds and Zimmer payments. Sufficient runway reduces short‑term financing risk and gives time to prove commercial traction; inadequate runway forces dilutive capital raises that compress per‑share value.

    Watch: If revenue growth stalls and operating cash outflow reverts to prior higher levels, existing cash will be depleted quickly.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Cash increased from $1.46M (9/30/2024) to $6.57M (9/30/2025), reflecting April 2025 financing proceeds and Zimmer payments.

    Open source ↗
  • Zimmer’s exclusive distribution licenses materially lower go‑to‑market cost and accelerate hospital adoption compared with NeuroOne building its own global salesforce.HoldingMateriality: Medium

    MD&A/Item 1: Zimmer paid $3.0M upfront for an exclusive RF Distribution License and the company recognizes product revenue and milestone/milestone potential. If Zimmer executes, NeuroOne preserves capital and achieves faster adoption; if Zimmer underperforms or terminates, NeuroOne faces costly self‑build or must find another partner.

    Watch: Zimmer reduces commercialization effort, delays stocking/physician training, or terminates the agreement early.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    MD&A/Item 1: Zimmer paid $3.0M upfront for an exclusive RF Distribution License and the company recognizes product revenue and milestone/milestone.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Sustained revenue growth will be driven primarily by converting FDA 510(k) clearances and the Zimmer distribution license into repeat hospital and clinician purchases rather than one‑time milestone receipts or isolated limited releases. If commercial adoption via Zimmer scales, revenue and operating leverage will follow; if adoption stalls, the company will need more capital or face write‑downs.

Gross margins will stay positive and expand as higher‑volume sales of proprietary thin‑film electrodes and OneRF systems scale because these products carry favorable manufacturing economics vs. early R&D costs. Sustained positive gross margins enable gross profit to cover fixed SG&A and accelerate path to operating profitability.

Operating losses will shrink as revenue scales and SG&A/R&D spending becomes more leveraged, moving operating income toward break‑even without outsized additional R&D or commercialization spend. Progress to operating profitability reduces dilution risk and supports equity value; failure to achieve leverage forces additional financing at dilutive terms.

The company has sufficient near‑term cash runway to fund commercialization activity through FY2026 without immediate additional dilutive financing, provided operating cash outflow remains near FY2025’s level. Sufficient runway reduces short‑term financing risk and gives time to prove commercial traction; inadequate runway forces dilutive capital raises that compress per‑share value.

Zimmer’s exclusive distribution licenses materially lower go‑to‑market cost and accelerate hospital adoption compared with NeuroOne building its own global salesforce. If Zimmer executes, NeuroOne preserves capital and achieves faster adoption; if Zimmer underperforms or terminates, NeuroOne faces costly self‑build or must find another partner.

All standing thesis claims
Original report summary

NeuroOne’s value depends on converting FDA-cleared thin-film electrode and OneRF ablation products into growing, high-margin commercial sales via its Zimmer distribution partnership while controlling R&D and commercialization spend.

Evidence assessed Nov 8, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for NEUROONE MEDICAL TECHNOLOGIES

Where the evidence on NEUROONE MEDICAL TECHNOLOGIES stands: Holding on the latest evidence (Nov 8, 2026). Of its 5 thesis points, 2 strengthening and 3 holding.

Bull case: what the evidence supports

  • Sustained revenue growth will be driven primarily by converting FDA 510(k) clearances and the Zimmer distribution license into repeat hospital and clinician purchases rather than one‑time milestone receipts or isolated limited releases.

    sec.gov ↗

  • Gross margins will stay positive and expand as higher‑volume sales of proprietary thin‑film electrodes and OneRF systems scale because these products carry favorable manufacturing economics vs. early R&D costs.

    sec.gov ↗

  • Operating losses will shrink as revenue scales and SG&A/R&D spending becomes more leveraged, moving operating income toward break‑even without outsized additional R&D or commercialization spend.

    sec.gov ↗

  • The company has sufficient near‑term cash runway to fund commercialization activity through FY2026 without immediate additional dilutive financing, provided operating cash outflow remains near FY2025’s level.

    sec.gov ↗

  • Zimmer’s exclusive distribution licenses materially lower go‑to‑market cost and accelerate hospital adoption compared with NeuroOne building its own global salesforce.

    sec.gov ↗

Bear case: what would count against it

  • Zimmer fails to ramp commercialization or reduces promotion for Evo/OneRF, leaving NeuroOne to build sales capacity itself.

    sec.gov ↗

  • Supplier cost inflation or tariffs materially raise component costs (MD&A cites supplier price increases and tariffs).

    sec.gov ↗

  • Company must materially increase commercialization spending (field sales, training) beyond current plans to penetrate hospitals outside Zimmer’s support.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · NEUROONE MEDICAL TECHNOLOGIES

Loading the break-condition record for NEUROONE MEDICAL TECHNOLOGIES.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    NEUROONE MEDICAL TECHNOLOGIES filed an SEC 8-K on 2026-10-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Other material event.

    NEUROONE MEDICAL TECHNOLOGIES filed an SEC 8-K on 2026-08-27: Other material event. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    NEUROONE MEDICAL TECHNOLOGIES filed an SEC 8-K on 2026-08-13: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Zimmer fails to ramp commercialization or reduces promotion for Evo/OneRF, leaving NeuroOne to build sales capacity itself.
  • Supplier cost inflation or tariffs materially raise component costs (MD&A cites supplier price increases and tariffs).
  • Company must materially increase commercialization spending (field sales, training) beyond current plans to penetrate hospitals outside Zimmer’s support.
  • If revenue growth stalls and operating cash outflow reverts to prior higher levels, existing cash will be depleted quickly.
  • Zimmer reduces commercialization effort, delays stocking/physician training, or terminates the agreement early.

NMTC news

Loading headlines…

Financial statements

NMTC income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.